TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News

TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

Is TRACON Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals or view top-rated stocks.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for TRACON Pharmaceuticals.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings results on Wednesday, May, 11th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.07. During the same period in the previous year, the company posted ($0.33) earnings per share.
View TRACON Pharmaceuticals' earnings history.

What price target have analysts set for TCON?

3 brokers have issued twelve-month target prices for TRACON Pharmaceuticals' shares. Their forecasts range from $10.00 to $13.00. On average, they expect TRACON Pharmaceuticals' share price to reach $11.50 in the next year. This suggests a possible upside of 511.7% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:

• Dr. Charles P. Theuer M.D., Ph.D., CEO, Pres & Director (Age 58, Pay $827.53k)
• Mr. Scott B. Brown CPA, M.S., Chief Financial Officer (Age 41, Pay $459.21k)
• Mr. Mark C. Wiggins M.B.A., Chief Bus. Officer (Age 66, Pay $506.25k)
• Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 45)
• Mr. Shahe Garabedian, Sr. VP & Head of Quality Assurance
• Dr. James L. Freddo, Chief Medical Officer (Age 67)
• Mr. Ya Huang, Exec. Director of Statistical Programming
• Dr. Brenda Marczi Pharm.D., Pharmd Mba, Sr. VP of Regulatory Affairs

Who are some of TRACON Pharmaceuticals' key competitors?

Some companies that are related to TRACON Pharmaceuticals include ARYA Sciences Acquisition Corp IV (ARYD), DBV Technologies (DBVT), Graphite Bio (GRPH), Cellectis (CLLS), Gamida Cell (GMDA), Poseida Therapeutics (PSTX), CEL-SCI (CVM), Ikena Oncology (IKNA), Acumen Pharmaceuticals (ABOS), Omega Therapeutics (OMGA), INmune Bio (INMB), Oyster Point Pharma (OYST), CEL-SCI (CVM), Big Cypress Acquisition (BCYP) and Taysha Gene Therapies (TSHA).
View all of TCON's competitors.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.97%), Bank of New York Mellon Corp (0.72%), Renaissance Technologies LLC (0.15%), Jane Street Group LLC (0.05%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends for TRACON Pharmaceuticals.

Which major investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for TRACON Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying TRACON Pharmaceuticals stock?

TCON stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jane Street Group LLC, and Simplex Trading LLC. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier, and Scott B Brown.
View insider buying and selling activity for TRACON Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $1.88.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals has a market capitalization of $37.75 million and generates $350 thousand in revenue each year. The biopharmaceutical company earns $-28.67 million in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does TRACON Pharmaceuticals have?

TRACON Pharmaceuticals employs 19 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at [email protected], or via fax at 858-550-0786.